Sandwich Shoppe Sold
On Friday, it was announced that the former Pfizer R&D center in Kent, UK, was sold: The new agreement with Discovery Park will see the consortium take over 297 acres…
Menu
Bye bye Bapi
We were disappointed to read this yesterday: Pfizer ($PFE) and Johnson & Johnson ($JNJ) have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase…
Slow summer? Hardly
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
Pricing as a product differentiator
A recent article in Forbes by ex-Pfizer President or R&D John LaMattina asks a provocative question: Will Pricing Be a Key Differentiator For New Drugs? I recall some 10-15 years…
Factors for successful virtual medtech
Our good friend Raman Minhas at ATPBio has a really good post today on the critical factors for a medtech company to be successful using a virtual organizational model. Raman's…
Observations from BIO 2012
As with BIO 2011, the bulk of our time was spent in the One-on-One Partnering sessions. More general reviews are found here, here, and here. As usual, BIO put on…
Digital Marketing by Pharma Continues
While we were all burning shoe leather at BIO2012 this week, the good folks at eMarketer published an interesting article on digital marketing by pharma: Digital advertising spending by the…
Unmeet needs should drive drug development, not money
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
IBD: Problem is worse than we suspected
In researching our latest project, we came across some startling statistics. A report published by the Crohn's and Colotis Foundation of Canada noted: This landmark document revealed that over 200,000…
Need for new drug delivery technologies is greater than ever
So said Shams Ruston from Labopharm at last week's Interphex conference in New York. We happen to agree. In fact, there are two ways to look at this. From the…
- Go to the previous page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- …
- 32
- Go to the next page